ADMA - ADMA Biologics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ADMA is currently covered by 4 analysts with an average price target of $26.39. This is a potential upside of $5.19 (24.48%) from yesterday's end of day stock price of $21.2.

ADMA Biologics's activity chart (see below) currently has 28 price targets and 54 ratings on display. The stock rating distribution of ADMA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 80.79% with an average time for these price targets to be met of 822.14 days.

Highest price target for ADMA is $26, Lowest price target is $14, average price target is $22.5.

Most recent stock forecast was given by KRISTEN KLUSKA from CANTOR FITZGERALD on 04-Mar-2025. First documented stock forecast 09-Sep-2015.

Currently out of the existing stock ratings of ADMA, 24 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$25

$1.48 (6.29%)

$20

2 months 5 days ago
(04-Mar-2025)

8/9 (88.89%)

$7.99 (46.97%)

138

Buy

$25

$1.48 (6.29%)

$10

6 months 1 days ago
(08-Nov-2024)

5/6 (83.33%)

$2.38 (10.52%)

632

Buy

$26

$2.48 (10.54%)

$18

6 months 1 days ago
(08-Nov-2024)

14/15 (93.33%)

$3.38 (14.94%)

298

$14

$-9.52 (-40.48%)

$12

10 months 19 days ago
(20-Jun-2024)

7/7 (100%)

$3.29 (30.72%)

529

Buy

$4

$-19.52 (-82.99%)

$7

4 years 6 months 3 days ago
(06-Nov-2020)

6/6 (100%)

$2.09 (109.42%)

1736

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ADMA (ADMA Biologics) average time for price targets to be met?

On average it took 822.14 days on average for the stock forecasts to be realized with a an average price target met ratio 80.79

Which analyst has the current highest performing score on ADMA (ADMA Biologics) with a proven track record?

JASON KOLBERT

Which analyst has the current lower performing score on ADMA (ADMA Biologics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on ADMA (ADMA Biologics)?

Jason Kolbert has 5 price targets and 11 ratings on ADMA

Which analyst is the currently most bullish on ADMA (ADMA Biologics)?

Raghuram Selvaraju with highest potential upside - $2.48

Which analyst is the currently most reserved on ADMA (ADMA Biologics)?

Leland Gershell with lowest potential downside - -$19.52

ADMA Biologics in the News

Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know

Adma Biologics (ADMA) closed the latest trading day at $23.52, indicating a +1.07% change from the previous session’s end. The stock’s performance was behind the S&P 500’s daily gain of 1.47%. At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%. Heading into today, shares of the infectious disease drug developer...

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?

ADMA Biologics ADMA is scheduled to report first-quarter 2025 results on May 7, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $119.1 million and 16 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Earnings estimate for 2025 has increased to 71 cents...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?